Citigroup reiterates Mylan at buy

Mylan Laboratories Inc. was reiterated by Citigroup Investment Research analyst Andrew Swanson at a buy rating on news that the company will report its third-quarter 2006 results on Feb. 2. Citigroup forecasts $0.25 per share (versus earnings of $0.13 in the fiscal third quarter of 2005), one cent above the consensus expectation of $0.24. The analyst forecasts revenues of $309.7 million. Pending launches of Ditropan XL and nebivolol should positively impact for fiscal 2007. Shares of the Canonsburg, Pa., pharmaceutical company were down 57 cents, or 2.87%, at $19.30 on volume of 2,404,000 shares versus the three-month running average of 1,306,900 shares. (NYSE: MYL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.